Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia

This publication has 84 references indexed in Scilit:

• A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls
  World Psychiatry, 2013
• Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
  Schizophrenia Bulletin, 2011
• Sex Differences in Lipid and Lipoprotein Metabolism: It's Not Just about Sex Hormones
  The Journal of Clinical Endocrinology & Metabolism, 2011
• Antipsychotic drugs and obesity
  Trends in Molecular Medicine, 2011
• Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
  Schizophrenia Research, 2010
• Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study
  Schizophrenia Research, 2010
• Combined hyperlipidemia in relation to race/ethnicity, obesity, and insulin resistance in the Multi-Ethnic Study of Atherosclerosis
  Metabolism, 2009
• Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
  Schizophrenia Research, 2008
• Secondary Effects of Antipsychotics: Women at Greater Risk Than Men
  Schizophrenia Bulletin, 2008
• The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review
  Journal of Internal Medicine, 2004